Welcome to our dedicated page for Capricor Therapeutics SEC filings (Ticker: CAPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Capricor Therapeutics’ cell-therapy disclosures isn’t easy. Clinical trial tables, exosome manufacturing risks, and milestone payment clauses stretch across hundreds of pages, leaving many investors asking, “How do I understand Capricor Therapeutics SEC filings explained simply?”
Stock Titan solves that problem. Our AI-powered summaries translate every 10-K annual report, 10-Q quarterly earnings report, and 8-K material event into clear language, then link you directly to the source page for deeper review. Need real-time alerts? “Capricor Therapeutics Form 4 insider transactions” and “Capricor Therapeutics executive stock transactions Form 4” appear on your dashboard within minutes of hitting EDGAR. You can even ask natural questions like “What did management disclose in the latest Capricor Therapeutics proxy statement executive compensation?” and receive instant answers.
Why does this matter? Capricor’s filings reveal when CAP-1002 reaches a trial milestone, how R&D spending affects cash runway, and whether new licensing deals alter revenue forecasts. Our platform highlights:
- Clinical-stage updates in 8-K material events explained
- Segment R&D costs inside a Capricor Therapeutics earnings report filing analysis
- Board and officer ownership changes via Capricor Therapeutics Form 4 insider transactions real-time
With comprehensive coverage of all SEC documents, AI-driven red-flag detection, and expert commentary, you’ll spend less time searching and more time making informed decisions. Start understanding Capricor Therapeutics SEC documents with AI today—no biotech PhD required.
Capricor Therapeutics, Inc. (CAPR) reported total assets of $133.6 million and held approximately $122.8 million in combined cash, cash equivalents and marketable securities as of June 30, 2025. Marketable securities declined to $99.56 million from $140.23 million at year-end 2024 while cash and cash equivalents increased to $23.24 million from $11.29 million. Total stockholders' equity was $104.98 million and the accumulated deficit grew to approximately $250.1 million.
The company recorded a net loss of $25.9 million for the three months ended June 30, 2025 and $50.3 million for the six months ended June 30, 2025, driven by higher research and development expense ($22.0 million in the quarter; $41.0 million for six months) and increased general and administrative costs. The filing discloses conversion of a CIRM grant to a proposed loan with potential accrued interest up to about $7.1 million and notes recent securities and derivative lawsuits filed in July and August 2025. The company states it will require substantial additional capital to fund operations and may seek equity, debt, partnerships, or government grants.
Capricor Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is attached as Exhibit 99.1. The company states the release is being furnished, not filed, and therefore is not subject to Section 18 liability and will not be incorporated by reference into other Exchange Act filings unless expressly stated. The filing also includes a Cover Page Interactive Data File (inline XBRL) as Exhibit 104. The report identifies Capricor common stock trading as CAPR on The Nasdaq Capital Market and is signed by CEO Linda Marbán, Ph.D.. Investors should review Exhibit 99.1 for the detailed financial figures because the 8-K text here provides only the notice of the release.
FAQ
What is the current stock price of Capricor Therapeutics (CAPR)?
What is the market cap of Capricor Therapeutics (CAPR)?
